Evidence map›Paper›PMID 36325179›Full record

ArticlePeerJ2022

Prevention of polycystic ovary syndrome and postmenopausal osteoporosis by inhibiting apoptosis with Shenling Baizhu powder compound.

Jing Liang, Ai-Li Bao, Hong-Yu Ma, Wei Dong, Wei-Hua Li, Xi Wu, Han-Yu Li, Hai-Yan Hou, Ya-Qiong Chen, Jia-Lin Fu and 1 more

Open access · goldAbstract read
In one paragraph

Article in PeerJ, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Jing Liang *Department of Gynecology, Guang'anmen South Area Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Ai-Li Bao *Department of Gynecology, Guang'anmen South Area Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Hong-Yu MaHebei General Hospital, Department of Traditional Chinese Medicine, Hebei, Chinese.
Wei DongDepartment of Gynecology, Guang'anmen South Area Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Wei-Hua LiDepartment of Gynecology, Guang'anmen South Area Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Xi WuDepartment of Gynecology, Guang'anmen South Area Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Han-Yu LiDepartment of Gynecology, Guang'anmen South Area Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Hai-Yan HouDepartment of Obstetrics and Gynecology, Characteristic Medical Center of Chinese People's Armed Police Force, Tianjin, China.
Ya-Qiong ChenDepartment of Obstetrics and Gynecology, Characteristic Medical Center of Chinese People's Armed Police Force, Tianjin, China.
Jia-Lin FuDepartment of Gynecology, Guang'anmen South Area Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Chao ShaoDepartment of Gynecology, Guang'anmen South Area Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNGuang’anmen Hospital · CNChinese People's Armed Police ForceHebei General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Shenling Baizhu powder (SBP) has been shown to reverse the abnormal expression of the aromatic hydrocarbon receptor (AHR) mediated by air pollution. Our study aimed to understand the main ingredient of SBP and investigate its action mechanism in preventing polycystic ovary syndrome (POCS) and postmenopausal osteoporosis (PMO). Methods: The active ingredients of SBP with the highest binding affinity to AHR were screened using a Chinese medicine database, and their binding mechanism was simulated using molecular dynamics simulation (MDS). Rutin was utilized to treat ovarian granulosa cell lines and osteoblast cell lines. The cell lines were treated with a gradient of rutin concentration (0.01 mmol/L, 0.05 mmol/L and 0.1 mmol/L) to find the optimal drug dose. PCR was used to detect AHR and apoptosis-related proteins, and WB to detect the expression of AHR, caspase-3 and cleaved-caspase-3. Finally, the CCK-8 cell proliferation assay detected the proliferation of cells. Results: We obtained Rutin through the Chinese medicine database, and dynamics simulation determined its binding sites. Ovarian granulosa cell lines and osteoblast cell lines were treated with Rutin. RT-PCR and western blotting revealed that the expression of apoptosis-associated protein Bcl-2 was elevated, and the expression of AHR, Bax, caspase-3 and PARP were decreased. CCK-8 results showed accelerated proliferation in both cell types. Conclusion: Rutin, the main ingredient of SBP compound, works by binding to AHR, which can improve POCS and PMO by inhibiting cell apoptosis and by promoting cell proliferation.

Indexed as

Drugs, Chinese HerbalOsteoporosis, PostmenopausalPolycystic Ovary SyndromeApoptosisApoptosis Regulatory ProteinsCaspase 3FemaleHumansPowdersApoptosis Regulatory ProteinsBaizhuCaspase 3Drugs, Chinese HerbalPowdersAromatic hydrocarbon receptor (AHR)Cell apoptosisPolycystic ovary syndrome (POCS)Postmenopausal osteoporosis (PMO)Shenling Baizhu powder compound

Identifiers

PMID36325179
PMCPMC9620975
OpenAlexW4307700198

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.